BIO.B Relative Valuation
BIO.B's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BIO.B is overvalued; if below, it's undervalued.
Historical Valuation
Bio Rad Laboratories Inc (BIO.B) is now in the Overvalued zone, suggesting that its current forward PE ratio of 30.14 is considered Overvalued compared with the five-year average of 28.92. The fair price of Bio Rad Laboratories Inc (BIO.B) is between 267.05 to 302.80 according to relative valuation methord. Compared to the current price of 310.70 USD , Bio Rad Laboratories Inc is Overvalued By 2.61%.
Relative Value
Fair Zone
267.05-302.80
Current Price：310.70
2.61%
Overvalued
30.42
PE
1Y
3Y
5Y
Trailing
Forward
17.86
EV/EBITDA
Bio Rad Laboratories Inc. (BIO.B) has a current EV/EBITDA of 17.86. The 5-year average EV/EBITDA is 17.17. The thresholds are as follows: Strongly Undervalued below 14.03, Undervalued between 14.03 and 15.60, Fairly Valued between 18.74 and 15.60, Overvalued between 18.74 and 20.31, and Strongly Overvalued above 20.31. The current Forward EV/EBITDA of 17.86 falls within the Historic Trend Line -Fairly Valued range.
25.96
EV/EBIT
Bio Rad Laboratories Inc. (BIO.B) has a current EV/EBIT of 25.96. The 5-year average EV/EBIT is 24.06. The thresholds are as follows: Strongly Undervalued below 20.19, Undervalued between 20.19 and 22.13, Fairly Valued between 26.00 and 22.13, Overvalued between 26.00 and 27.93, and Strongly Overvalued above 27.93. The current Forward EV/EBIT of 25.96 falls within the Historic Trend Line -Fairly Valued range.
3.25
PS
Bio Rad Laboratories Inc. (BIO.B) has a current PS of 3.25. The 5-year average PS is 3.27. The thresholds are as follows: Strongly Undervalued below 2.51, Undervalued between 2.51 and 2.89, Fairly Valued between 3.65 and 2.89, Overvalued between 3.65 and 4.03, and Strongly Overvalued above 4.03. The current Forward PS of 3.25 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Bio Rad Laboratories Inc. (BIO.B) has a current P/OCF of 0.00. The 5-year average P/OCF is 3.65. The thresholds are as follows: Strongly Undervalued below -7.97, Undervalued between -7.97 and -2.16, Fairly Valued between 9.47 and -2.16, Overvalued between 9.47 and 15.28, and Strongly Overvalued above 15.28. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Bio Rad Laboratories Inc. (BIO.B) has a current P/FCF of 0.00. The 5-year average P/FCF is 4.71. The thresholds are as follows: Strongly Undervalued below -10.28, Undervalued between -10.28 and -2.78, Fairly Valued between 12.20 and -2.78, Overvalued between 12.20 and 19.69, and Strongly Overvalued above 19.69. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Bio Rad Laboratories Inc (BIO.B) has a current Price-to-Book (P/B) ratio of 1.28. Compared to its 3-year average P/B ratio of 1.20 , the current P/B ratio is approximately 6.80% higher. Relative to its 5-year average P/B ratio of 1.20, the current P/B ratio is about 6.80% higher. Bio Rad Laboratories Inc (BIO.B) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 3.53%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 3.53% , the current FCF yield is about -100.00% lower.
1.28
P/B
Median3y
1.20
Median5y
1.20
3.92
FCF Yield
Median3y
3.53
Median5y
3.53
Competitors Valuation Multiple
The average P/S ratio for BIO.B's competitors is , providing a benchmark for relative valuation. Bio Rad Laboratories Inc Corp (BIO.B) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 0.50%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of BIO.B decreased by 4.58% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -5.28 to -13.03.
The secondary factor is the Revenue Growth, contributed 0.50%to the performance.
Overall, the performance of BIO.B in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Bio Rad Laboratories Inc (BIO.B) currently overvalued or undervalued?
What is Bio Rad Laboratories Inc (BIO.B) fair value?
How does BIO.B's valuation metrics compare to the industry average?
What is the current P/B ratio for Bio Rad Laboratories Inc (BIO.B) as of Dec 05 2025?
What is the current FCF Yield for Bio Rad Laboratories Inc (BIO.B) as of Dec 05 2025?
What is the current Forward P/E ratio for Bio Rad Laboratories Inc (BIO.B) as of Dec 05 2025?